Home  »  Technology   »  What Do Analysts Think Of Second Sight Medical Pro...

What Do Analysts Think Of Second Sight Medical Products Inc. (EYES)

How have the shares performed?

Second Sight Medical Products Inc. (EYES) saw an uptrend of 9.32% in the recent trading with $7.27 being its most recent. The current price level -63.65% lower than the highest price of $20.00 marked by the stock while trading over the past 52-weeks, whereas it is 952.71% higher than the lowest price of $0.69 the company dropped to over past 52-weeks. The latest news story on EYES appeared in Insider Monkey under the title “Is Second Sight Medical Products Inc (EYES) A Good Stock To Buy?” on Jun-14-21.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Squeezing the time span to 30 day period shows us the stock is currently trading -2.15% below one month high and is +52.09% above of the lowest during that time. Looking into the simple moving average, Second Sight Medical Products Inc. (EYES)’s stock stands at a SMA-50 of $6.54 while that of 5-day is reading $6.58.

Daily rise and fall of price influence many of the traders, and in order to overcome the fluctuating effect of that and to watch the stock closely, traders focus more on stock’s 200-day moving average. At various points in trading activity, investors are more likely to be making use of that measure as a strong indicator in figuring out their support and resistance levels, and EYES’s SMA-200 as of now is $3.67.

Do analysts rate it as a buy, sell or hold?

Irrespective of recent performance, what’s important is what the future holds. In uncertain economic times, a clear picture is difficult to get. Analysts generally have a good understanding of the market works, which gives them a leg up in making predictions. Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.

Second Sight Medical Products Inc. Earnings – What Happened With EYES

Coming around sales and income figures, publically trading companies under normal circumstances post earnings and revenues near to average estimates by the Wall Street analysts, but those could came either above or below estimates and known as surprise factor. Second Sight Medical Products Inc. (EYES) last released financial results for the quarter that ended 6/29/2020, posting a surprise factor of 63.40% for net revenue.

EYES – Second Sight Medical Products Inc. Stock Earnings Estimates

The perspective of Second Sight Medical Products Inc. (NASDAQ:EYES)’s current quarter earnings identifies that analysts are in consensus over the estimate of -0.41 for stock’s EPS in the current quarter. Company’s EPS for the last quarter was -0.15.

Investors get the exact data about the key information of institutional ownership in a listed company through its 13F filings at the Stock Exchange Commission (SEC). The total number of common shares currently owned by the public is 23.54 million. EYES does have institutional investors; and they hold 12.10% of the stock.

Second Sight Medical Products Inc. – Insider Activity and Holdings

As on Mar 30, 2021, Hudson Bay Capital Management LP was the top most holder in Second Sight Medical Products Inc. (NASDAQ:EYES) with an ownership of 1.0 million shares of the company or 3.58% of the stake worth $8.25 million. The filing also reveals Sabby Management, LLC as the second largest holder in the company with a control over 3.30% of the outstanding shares. Its stake is worth $7.61 million for having 0.92 million shares in hand.

Vanguard Group, Inc. (The) also came holding a key position in the company during the recent quarter and it now holds 2.20% of the outstanding shares. With this there are now 33 institutions which have possession in EYES’s shares.

Currently, the stock has been recommended as Moderate Buy by 1 of the brokerage firms. Analyst ratings are often compiled into a single score from 1 to 5. The score of 1 signifies buy or strong buy, the score of 2 signifies outperform, the score of 3 means hold, and the score of 4 indicates underperform. The simple numeric range of brokerage firm referenced at the scale of 1 to 5 reads a current average recommendation of 2.00 for the stock.

The liquidity is a key characteristic of any stock and is the main point of focus of both short-term as well as long term investors before start trading into a stock. In recently reported quarter, current ratio recorded by Second Sight Medical Products Inc. was 0.83 while posting a debt to equity ratio of 0.10.

Second Sight Medical Products Inc.’s return on equity, or ROE, is -154.00%, compared to the industry average of -0.59% for Healthcare – Medical Devices. Although this indicates that EYES fails to use its equity well, the metric will vary significantly depending on the industry.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

Technical Analysis of Second Sight Medical Products Inc. (NASDAQ:EYES) stock

To comprehend better with the trade moves and investors’ behavior, exploring the short, medium and long term technical indicators along with average volume of a stock is an effective way to make use of. When looking into those indicators for Second Sight Medical Products Inc. (EYES), we notice that the stock’s 20-day average volume is at 4,931,095 shares. Medium term indicators at an average of 100% are spotting the stock at Buy with its 50-day average volume of 7,218,730 shares. And to end, EYES’s 100-day average volume is 17,890,340 shares with 100% of the long-term indicators pointing towards Buy for the stock.

Leave a Comment

Your email address will not be published. Required fields are marked *

More Posts

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam